LRP4 Gene (LDL Receptor Related Protein 4)

Key regulator of neuromuscular junction formation and bone development

Gene Information Card

Symbol LRP4
Full Name LDL Receptor Related Protein 4
Gene Type protein-coding
Chromosomal Location 11p11.2
NCBI Gene ID 4038 ncbi.nlm.nih.gov/gene/4038
Ensembl ID ENSG00000134569
UniProt ID O75096
OMIM ID 604270
HGNC ID 6696
Aliases CLSS, LRP-4, MEGF7, SOST2

Description

LRP4 encodes a member of the low-density lipoprotein receptor (LDLR) family. The protein functions as a receptor for agrin and is critical for neuromuscular junction formation. It also acts as a negative regulator of bone growth by binding sclerostin and facilitating its inhibitory effect on Wnt signaling. Mutations in LRP4 cause Cenani-Lenz syndactyly syndrome and sclerosteosis 2, and variants are associated with myasthenia gravis.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Cenani-Lenz syndactyly syndrome Loss-of-function mutations disrupt limb development OMIM #212780
Sclerosteosis 2 Loss-of-function mutations impair sclerostin binding, leading to increased bone density OMIM #614305
Congenital myasthenic syndrome Mutations impair agrin-LRP4 signaling at the neuromuscular junction ClinVar, PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Skeletal muscle 12.5 Medium
Bone 8.3 Medium
Kidney 6.1 Low
Liver 4.2 Low
Brain 3.8 Low
Cell Line Expression
Cell Line nTPM Notes
HEK 293 15.2 High expression in recombinant systems
C2C12 (myoblast) 10.1 Endogenous expression
HepG2 5.4 Moderate expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.350C>T (p.Pro117Leu) Missense Rare Loss of function; associated with Cenani-Lenz syndrome
c.499G>A (p.Gly167Arg) Missense Rare Loss of function; associated with sclerosteosis 2
c.1195C>T (p.Arg399Trp) Missense Rare Impaired agrin binding; associated with myasthenia gravis
Mutation functional classification

Loss of Function (LOF)

Most LRP4 mutations are loss-of-function, leading to impaired agrin signaling (neuromuscular junction) or reduced sclerostin binding (bone overgrowth).

Gain of Function (GOF)

No gain-of-function mutations reported in LRP4.

Dominant Negative (DN)

Some missense mutations may exert dominant-negative effects by disrupting receptor dimerization, but evidence is limited.

Pathways

Agrin-LRP4-MuSK signaling in neuromuscular junction
Wnt signaling pathway (regulation by sclerostin)
LDL receptor family member signaling

Protein Summary

LRP4 is a single-pass transmembrane protein of the LDL receptor family. It contains multiple ligand-binding repeats and is essential for agrin-induced clustering of acetylcholine receptors at the neuromuscular junction. In bone, LRP4 binds sclerostin (SOST) to inhibit Wnt signaling, thereby regulating bone mass. The protein is expressed in skeletal muscle, bone, kidney, and liver. Mutations cause skeletal and neuromuscular disorders.

Related Products

Product name Cat.No. Species Gene ID
LRP4 Knockout HEK293 Cell Line EDJ-KQ2606 Human 4038 Details Get a Quote
NLRP4 Knockout HEK293 Cell Line EDJ-KQ9990 Human 147945 Details Get a Quote
LRP4 Knockout A-549 Cell Line EDJ-KQ21946 Human 4038 Details Get a Quote
LRP4 Knockout HCT 116 Cell Line EDJ-KQ23315 Human 4038 Details Get a Quote
LRP4 Knockout HeLa Cell Line EDJ-KQ23316 Human 4038 Details Get a Quote
NLRP4 Knockout HeLa Cell Line EDJ-KQ58591 Human 147945 Details Get a Quote
NLRP4 Knockout A-549 Cell Line EDJ-KQ67078 Human 147945 Details Get a Quote
NLRP4 Knockout HCT 116 Cell Line EDJ-KQ75483 Human 147945 Details Get a Quote
Displaying Records 1 To 8 Of 8 Records
Contact Us
*
*
*
*
How did you hear about us: